In vitro and in vivo, we found ovarian cancer cell death to be similarly pronounced in both Caspase 8 high-expressing and low-expressing ovarian cancers after combined treatment, suggesting that survival benefits may be possible with this therapeutic approach. Here, CASP8 is linked to ovarian carcinoma.